Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(36%)
Results Posted
60%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
2
18%
Ph early_phase_1
5
45%
Ph phase_2
2
18%
Ph not_applicable
2
18%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
5(45.5%)
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
2(18.2%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Recruiting3
Terminated1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 15 (45.5%)
Phase 12 (18.2%)
Phase 22 (18.2%)
N/A2 (18.2%)

Trials by Status

terminated19%
completed545%
withdrawn19%
active_not_recruiting19%
recruiting327%

Recent Activity

4 active trials
Showing 5 of 11
recruitingearly_phase_1

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT05555550
active_not_recruitingearly_phase_1

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

NCT04018053
recruitingphase_2

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
recruitingphase_1

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
terminatedphase_1

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

NCT03276676
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05555550Early Phase 1

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Recruiting
NCT04018053Early Phase 1

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Active Not Recruiting
NCT05554302Phase 2

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Recruiting
NCT06062745Phase 1

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Recruiting
NCT03276676Phase 1

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Terminated
NCT04852523Early Phase 1

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

Completed
NCT05035732Not Applicable

A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)

Withdrawn
NCT03188354Not Applicable

Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma

Completed
NCT04114370Early Phase 1

Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma

Completed
NCT03930173Early Phase 1

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

Completed
NCT03263780Phase 2

High Resolution PET-MRI Before Prostate Cancer HIFU

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11